Other GLP-1 receptor agonists have shown comparable results
Although GLP-1 signaling interacts with other metabolic systems, evidence in the supplied papers supports a primary role in reducing food intake and externally driven eating rather than a simple generalized increase in energy expenditure
No complaints! This is my third week with Rivas Medical Weight Loss and I have already lost 14 pounds in the first two weeks
A manufacturer has spent millions testing their product under controlled conditions for 24 to 36 months
I called, was put on hold then transferred to an escalation line, then they accidentally hung up on me and eventually called me back
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
